Pulmonary arterial hypertension (PAH) remains a severe clinical condition despite the
availability over the past 15 years of multiple drugs interfering with the endothelin, nitric …

Patients with chronic lung diseases, particularly interstitial lung disease and chronic
obstructive pulmonary disease, frequently develop pulmonary hypertension, which results in …

Pulmonary hypertension (PH), defined by increased pressure within the pulmonary
vasculature, is a hemodynamic and pathophysiologic state present in a wide variety of …

Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary
pulmonary hypertension caused by pulmonary vascular remodelling. As a result of basic …

Background Morbidity and mortality in pulmonary arterial hypertension (PAH) remain high.
Activation of platelet-derived growth factor receptor, colony stimulating factor 1 receptor, and …

Survival in patients with pulmonary arterial hypertension (PAH) is closely related to right
ventricular (RV) function. Although pulmonary load is an important determinant of RV …

For most patients with chronic myeloid leukemia, tyrosine kinase inhibitors (TKIs) have
turned a fatal disease into a manageable chronic condition. Imatinib, the first BCR-ABL1 TKI …

The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple
and in some ways conflicting. The treatment algorithm usually includes different types of …

Since the late 1990s, there has been a steady decline in cancer-related mortality, in part
related to the introduction of so-called targeted therapies. Intended to interfere with a specific …

Abstract In 2005, the National Institutes of Health (NIH) Chronic Graft-versus-Host Disease
(GVHD) Consensus Response Criteria Working Group recommended several measures to …